Melinta Therapeutics Inc (NASDAQ:MLNT) traded down 6.9% during mid-day trading on Wednesday . The stock traded as low as $2.91 and last traded at $2.96, 970,295 shares traded hands during mid-day trading. A decline of 21% from the average session volume of 1,229,247 shares. The stock had previously closed at $3.18.
A number of research firms have recently commented on MLNT. Zacks Investment Research cut shares of Melinta Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, August 17th. HC Wainwright lowered shares of Melinta Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, August 12th. Cantor Fitzgerald set a $15.00 price objective on Melinta Therapeutics and gave the company a “buy” rating in a research report on Wednesday, June 19th. ValuEngine upgraded Melinta Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, September 4th. Finally, Gabelli reissued a “sell” rating on shares of Melinta Therapeutics in a report on Thursday, June 20th. Two research analysts have rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company. Melinta Therapeutics currently has an average rating of “Hold” and a consensus price target of $27.21.
The company has a current ratio of 1.18, a quick ratio of 0.87 and a debt-to-equity ratio of 1.11. The firm has a market cap of $44.55 million, a P/E ratio of -0.17 and a beta of 4.40. The company’s 50 day simple moving average is $2.92 and its 200-day simple moving average is $3.92.
A number of institutional investors have recently modified their holdings of MLNT. Royal Bank of Canada purchased a new stake in Melinta Therapeutics in the second quarter worth approximately $267,000. Jane Street Group LLC purchased a new stake in Melinta Therapeutics during the 2nd quarter valued at $297,000. D. E. Shaw & Co. Inc. bought a new position in shares of Melinta Therapeutics during the 2nd quarter valued at $357,000. Morgan Stanley lifted its holdings in shares of Melinta Therapeutics by 82.9% during the 2nd quarter. Morgan Stanley now owns 10,822 shares of the biotechnology company’s stock valued at $72,000 after buying an additional 4,906 shares during the period. Finally, Paloma Partners Management Co purchased a new position in shares of Melinta Therapeutics in the 2nd quarter worth $205,000. Institutional investors own 19.47% of the company’s stock.
Melinta Therapeutics Company Profile (NASDAQ:MLNT)
Melinta Therapeutics, Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens.
Further Reading: What is Elliott Wave theory?
Receive News & Ratings for Melinta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Melinta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.